复方斑蝥胶囊联合经导管肝动脉化疗栓塞术治疗肝细胞癌疗效及安全性评价  

Efficacy and Safety of Compound Cantharides Capsules Combined with Transhepatic Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma

作　　者：唐芬[1] 蒋洪春[1] 谭盛葵[2] TANG Fen;JIANG Hongchun;TAN Shengkui(Nanxishan Hospital of Guangxi Zhuang Autonomous Region,Guilin,Guangxi,China 541002;Guilin Medical College,Guilin,Guangxi,China 541010)

机构地区：[1]广西壮族自治区南溪山医院,广西桂林541002 [2]桂林医学院,广西桂林541010

出　　处：《中国药业》2021年第3期81-84,共4页China Pharmaceuticals

基　　金：国家自然科学基金[81860602]。

摘　　要：目的探讨复方斑蝥胶囊联合经导管肝动脉化疗栓塞术(TACE)治疗肝细胞癌(HCC)的疗效及安全性。方法选取广西壮族自治区南溪山医院2015年3月至2018年3月收治的HCC患者122例,按随机数字表法分为对照组和观察组,各61例。两组均予TACE治疗,观察组加用复方斑蝥胶囊治疗,两组患者均治疗12周。结果观察组的客观缓解率和疾病控制率分别为57.38%和91.80%,显著高于对照组的36.07%和75.41%(P<0.05);与治疗前比较,两组患者治疗4周后的血清甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)及血小板内皮细胞黏附分子-1(PECAM-1)的水平均呈降低趋势(P<0.05),且观察组显著低于对照组(P<0.05);两组不良反应发生率差异显著(P<0.05)。两组截止随访时间为术后6~36个月,中位时间为18个月;观察组和对照组术后1,2,3年的无瘤生存率分别为85.25%,73.77%,62.30%和78.69%,68.85%,57.38%,组间比较,差异无统计学意义(P>0.05)。结论TACE联合复方斑蝥胶囊治疗HCC疗效显著,能明显下调血清AFP,CEA,CA19-9,CA125,VEGF,bFGF,PECAM-1水平,抑制肿瘤标志物的异常表达,降低肝癌细胞的侵袭和增殖能力,缓解病情,减少药物毒副反应。Objective To investigate the efficacy and safety of Compound Cantharides Capsules combined with transhepatic arterial chemoembolization(TACE)in the treatment of hepatocellular carcinoma(HCC).Methods Totally 122 patients with HCC admitted to Nanxishan Hospital of Guangxi Zhuang Autonomous Region were selected and divided into the control group and the observation group according to the random number table method,61 cases in each group.The patients in the two groups were treated with TACE,on this basis,the patients in the observation group were additionally treated with Compound Cantharides Capsules.Both of groups were treated for 12 weeks.Results The objective remission rate(ORR)and disease control rate(DCR)in the observation group were 57.38%and91.80%,which were significantly higher than 36.07%and 75.41%in the control group(P<0.05).After 4 weeks of treatment,the levels of serum alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen125(CA125),vascular endothelial growth factor(VEGF),basic fibroblast growth factor(b FGF)and platelet endothelial cell adhesion molecule-1(PECAM-1)were significantly decreased compared with those before treatment(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).There was significant difference in the incidence of adverse reactions between the two groups(P<0.05).The cut-off follow-up time of the two groups was 6 to 36 months after the operation,and the median follow-up time was 18 months.The 1-,2-,3-year tumor-free survival rates of the observation group were85.25%,73.77%and 62.30%,which had no significant difference from 78.69%,68.85%,and 57.38%of the control group(P>0.05).Conclusion TACE combined with Compound Cantharides Capsules are effective in the treatment of HCC,which can significantly down-regulate the levels of serum AFP,CEA,CA19-9,CA125,VEGF,bFGF and PECAM-1,inhibit the abnormal expressions of tumor markers and reduce the ability of invasion and proliferation of HCC

关 键 词：肝细胞癌 复方斑蝥胶囊 经导管肝动脉化疗栓塞术 临床疗效 安全性 

分 类 号：R932[医药卫生—生药学] R285.6[医药卫生—药学]